TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
Read the article

ETOP-IBCSG Partners Foundation, Bern
Prof. Rolf A. Stahel is President of the ETOP-IBCSG Partners Foundation in Bern, Switzerland, and remains affiliated with University Hospital Zurich and the University of Zurich. His thoracic oncology research spans EGFR-, ALK- and KRAS-mutated non-small cell lung cancer, malignant pleural mesothelioma, and translational biomarker work. He co-founded the European Thoracic Oncology Platform and its Lungscape registry, led trials including the ETOP BOOSTER study, served as ESMO President, and received the 2025 ESMO Lifetime Achievement Award. He is also Vice-President of the International Cancer Foundation. He is a frequent speaker at major international thoracic oncology congresses.
Rolf A. Stahel
Programme Roster